Arcus Biosciences Inc (NYSE:RCUS) President Buys $113,850.00 in Stock

Arcus Biosciences Inc (NYSE:RCUS) President Juan C. Jaen acquired 15,000 shares of the business’s stock in a transaction that occurred on Friday, June 28th. The stock was purchased at an average cost of $7.59 per share, with a total value of $113,850.00. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link.

NYSE:RCUS traded down $0.36 during mid-day trading on Friday, hitting $8.17. 64,649 shares of the company traded hands, compared to its average volume of 178,713. The company has a fifty day moving average of $8.43. Arcus Biosciences Inc has a one year low of $7.15 and a one year high of $16.06. The company has a market cap of $363.85 million, a price-to-earnings ratio of -5.71 and a beta of 1.01.

Arcus Biosciences (NYSE:RCUS) last released its quarterly earnings results on Thursday, May 2nd. The company reported ($0.41) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.34) by ($0.07). Arcus Biosciences had a negative net margin of 613.46% and a negative return on equity of 22.72%. The company had revenue of $1.75 million for the quarter, compared to the consensus estimate of $1.25 million. Sell-side analysts forecast that Arcus Biosciences Inc will post -1.64 earnings per share for the current fiscal year.

Several institutional investors have recently made changes to their positions in RCUS. Bank of New York Mellon Corp lifted its position in shares of Arcus Biosciences by 32.0% in the third quarter. Bank of New York Mellon Corp now owns 21,185 shares of the company’s stock valued at $295,000 after acquiring an additional 5,138 shares in the last quarter. Vanguard Group Inc. lifted its position in shares of Arcus Biosciences by 2.8% in the third quarter. Vanguard Group Inc. now owns 452,409 shares of the company’s stock valued at $6,307,000 after acquiring an additional 12,511 shares in the last quarter. Rhumbline Advisers purchased a new position in shares of Arcus Biosciences in the fourth quarter valued at about $429,000. BlackRock Inc. lifted its position in shares of Arcus Biosciences by 295.5% in the fourth quarter. BlackRock Inc. now owns 1,721,894 shares of the company’s stock valued at $18,545,000 after acquiring an additional 1,286,470 shares in the last quarter. Finally, Citigroup Inc. lifted its position in shares of Arcus Biosciences by 104.5% in the fourth quarter. Citigroup Inc. now owns 11,395 shares of the company’s stock valued at $122,000 after acquiring an additional 5,824 shares in the last quarter. Institutional investors and hedge funds own 46.58% of the company’s stock.

Several analysts recently commented on RCUS shares. Zacks Investment Research lowered GENEL ENERGY PL/ADR from a “hold” rating to a “sell” rating in a report on Thursday, July 4th. Citigroup cut their price target on Tremont Mortgage Trust from $9.50 to $5.00 and set a “neutral” rating for the company in a report on Wednesday, June 5th. Finally, Svb Leerink reissued an “outperform” rating on shares of Arcus Biosciences in a report on Friday, May 3rd. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. Arcus Biosciences presently has a consensus rating of “Buy” and an average target price of $16.56.

Arcus Biosciences Company Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing cancer immunotherapies in the United States. The company develops various programs targeting immuno-oncology pathways, including AB928, a dual adenosine receptor antagonist, which is in a Phase I/Ib clinical trial; and AB122, an anti-PD-1 antibody that is in Phase I clinical trial.

Featured Article: Management Fee

Insider Buying and Selling by Quarter for Arcus Biosciences (NYSE:RCUS)

Receive News & Ratings for Arcus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.